This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

SynapDx Autism Gene Expression Analysis Study (SAGA)

This study has been completed.
Information provided by (Responsible Party):
SynapDx Identifier:
First received: October 23, 2012
Last updated: December 15, 2014
Last verified: December 2014

This study will prospectively enroll approximately 660 children, at least 18 months and less than 5 years of age, who have been referred to a pediatric developmental evaluation centers. Enrolled children will have blood drawn for RNA gene expression analysis and undergo a clinical evaluation to determine the presence or absence of a diagnosis of ASD.

The sequential co-primary objectives of this study are:

  • To develop an algorithm to classify blood RNA gene expression patterns to maximize agreement between the classification and a clinical assessment of presence or absence of Autism Spectrum Disorders (ASD).
  • To prospectively assess the clinical sensitivity and specificity of the blood RNA gene expression classification algorithm (the SDX-002 test) in children referred to a developmental evaluation clinic for a possible developmental disorder.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: SynapDx Autism Spectrum Disorder Gene Expression Analysis Study

Resource links provided by NLM:

Further study details as provided by SynapDx:

Primary Outcome Measures:
  • RNA gene expression in peripheral blood [ Time Frame: within 30 days of collection ]

Biospecimen Retention:   Samples With DNA

Estimated Enrollment: 660
Study Start Date: October 2012
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Development group 1
Development group 2
Development group 3
Validation group


Ages Eligible for Study:   18 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Children 18 months to < 5 years referred to a developmental evaluation centers for evaluation of a possible developmental disorder.

Inclusion Criteria:

  1. Referred to a developmental evaluation centers for evaluation of a possible developmental disorder, other than isolated motor problems.
  2. Age >= 18 months and < 5 years.
  3. Parent/legal guardian has been informed about the study and has signed an informed consent form.

Exclusion Criteria:

  1. Prior reliable diagnosis of Autism Spectrum Disorder (i.e. prior evaluation by a multi-disciplinary team has already reliably established Autism Spectrum Disorder diagnosis).
  2. Unable or unwilling to complete study procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01716845

United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
  More Information

Responsible Party: SynapDx Identifier: NCT01716845     History of Changes
Other Study ID Numbers: 12001
Study First Received: October 23, 2012
Last Updated: December 15, 2014

Keywords provided by SynapDx:
autism spectrum disorders
gene expression
developmental delay

Additional relevant MeSH terms:
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders processed this record on August 16, 2017